Table 2.
Summary of urinary AMPA concentrations in European children (6–11 yrs.) from the HBM4EU-aligned studies.
| Study | LOD AMPA (µg/L) |
LOQ AMPA (µg/L) |
% < LOQ | AMPA (µg/L) | Creatinine-Adjusted AMPA (µg/g crt) c | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| P25 | P50 | P75 | P95 | P25 | P50 | P75 | P95 | ||||
| SLO CRP children a | 0.1 | 53 | <LOQ | <LOQ | 0.14 | 0.29 | 0.13 | 0.26 | |||
| ORGANIKO b | 0.03 | 0.1 | 25 | =LOQ | 0.17 | 0.28 | 0.66 | 0.05 | 0.15 | 0.23 | 0.57 |
| GerES V-sub a | 0.1 | 53 | <LOQ | <LOQ | 0.21 | 0.48 | 0.17 | 0.40 | |||
| 3XG b | 0.2 | 74 | <LOQ | <LOQ | 0.20 | 0.40 | 0.14 | 0.37 | |||
| ESTEBAN a | 0.02 | 0.05 | 4 | 0.11 | 0.18 | 0.24 | 0.43 | 0.12 | 0.19 | 0.30 | 0.59 |
| Combined data | 0.22 | 0.47 | 0.21 | 0.45 | |||||||
a: Biomarker data generated before HBM4EU QA/QC program but deemed comparable (see Esteban López et al., 2021) [17]; b: Biomarker data quality assured by HBM4EU QA/QC program; c: Values <LOQ set to LOQ/2.